Erik Bloomquist
Overview
Explore the profile of Erik Bloomquist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang E, Hahn N, Lerner S, Fallah J, Agrawal S, Kamat A, et al.
Bladder Cancer
. 2024 Jul;
9(3):271-286.
PMID: 38993184
Background: Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical...
2.
Heiss B, Chang E, Gao X, Truong T, Brave M, Bloomquist E, et al.
J Clin Oncol
. 2024 Mar;
42(15):1851-1860.
PMID: 38452327
Purpose: The US Food and Drug Administration (FDA) approved talazoparib with enzalutamide for first-line treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). Patients And...
3.
Fallah J, Xu J, Weinstock C, Brave M, Bloomquist E, Fiero M, et al.
J Clin Oncol
. 2023 Dec;
42(5):605-613.
PMID: 38127780
Purpose: This article summarizes the US Food and Drug Administration (FDA) review of the data leading to approval of olaparib plus abiraterone for the treatment of patients with deleterious or...
4.
Lee D, Gittleman H, Weinstock C, Suzman D, Bloomquist E, Agrawal S, et al.
Eur Urol
. 2023 Jun;
84(4):373-378.
PMID: 37271635
Background: While frontline immuno-oncology/tyrosine kinase inhibitor (IO/TKI) combination therapy has established a benefit in metastatic renal cell carcinoma (mRCC), this may differ by International Metastatic RCC Database Consortium (IMDC) risk...
5.
Royce M, Mulkey F, Osgood C, Bloomquist E, Amiri-Kordestani L
J Clin Oncol
. 2023 Apr;
41(18):3456-3457.
PMID: 37104738
No abstract available.
6.
Narayan P, Dilawari A, Osgood C, Feng Z, Bloomquist E, Pierce W, et al.
J Clin Oncol
. 2023 Feb;
41(11):2108-2116.
PMID: 36780610
Purpose: The US Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (DS-8201a, T-DXd) for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry...
7.
Royce M, Osgood C, Mulkey F, Bloomquist E, Pierce W, Roy A, et al.
J Clin Oncol
. 2022 Jan;
40(11):1155-1162.
PMID: 35084948
Purpose: The US Food and Drug Administration approved abemaciclib in combination with endocrine therapy (ET) for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor...
8.
Gao J, Cheng J, Prowell T, Bloomquist E, Tang S, Wedam S, et al.
Lancet Oncol
. 2021 Oct;
22(11):1573-1581.
PMID: 34656225
Background: Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are oral targeted agents approved for use in combination with endocrine therapy as first-line or second-line treatment of patients with hormone receptor-positive, HER2-negative, advanced...
9.
Lee E, Selig W, Meehan C, Bacha J, Barone A, Bloomquist E, et al.
Neuro Oncol
. 2021 Apr;
23(8):1252-1260.
PMID: 33822177
On July 24, 2020, a workshop sponsored by the National Brain Tumor Society was held on innovating brain tumor clinical trials based on lessons learned from the COVID-19 experience. Various...
10.
Anscher M, Chang E, Gao X, Gong Y, Weinstock C, Bloomquist E, et al.
Oncologist
. 2020 Nov;
26(2):139-146.
PMID: 33145877
The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castrate-resistant...